Accelerate Diagnostics, Inc. Logo

Accelerate Diagnostics, Inc.

AXDX

(1.8)
Stock Price

1,85 USD

-165.78% ROA

131.18% ROE

-1.17x PER

Market Cap.

45.464.448,00 USD

-121.16% DER

0% Yield

-310.57% NPM

Accelerate Diagnostics, Inc. Stock Analysis

Accelerate Diagnostics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Accelerate Diagnostics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (275.44%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-0.15x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a minimal amount of debt (-95%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

5 ROA

The stock's ROA (-151.1%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-3), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Accelerate Diagnostics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Accelerate Diagnostics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Accelerate Diagnostics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Accelerate Diagnostics, Inc. Revenue
Year Revenue Growth
1996 2.100.000
1997 2.500.000 16%
1998 7.381.445 66.13%
1999 2.897.984 -154.71%
2000 1.567.389 -84.89%
2001 855.660 -83.18%
2002 653.977 -30.84%
2003 850.570 23.11%
2004 118.614 -617.09%
2005 502.110 76.38%
2006 212.701 -136.06%
2007 183.130 -16.15%
2008 475.520 61.49%
2009 1.269.886 62.55%
2010 2.245.628 43.45%
2011 1.121.166 -100.29%
2012 236.000 -375.07%
2013 48.285 -388.76%
2014 122.000 60.42%
2015 147.000 17.01%
2016 246.000 40.24%
2017 4.177.000 94.11%
2018 5.670.000 26.33%
2019 9.297.000 39.01%
2020 11.165.000 16.73%
2021 11.782.000 5.24%
2022 12.752.000 7.61%
2023 13.196.000 3.36%
2023 12.059.000 -9.43%
2024 11.944.000 -0.96%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Accelerate Diagnostics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 100.000 100%
1998 68.772 -45.41%
1999 0 0%
2000 0 0%
2001 123.486 100%
2002 326.582 62.19%
2003 568.873 42.59%
2004 554.416 -2.61%
2005 1.304.888 57.51%
2006 2.155.988 39.48%
2007 991.581 -117.43%
2008 880.984 -12.55%
2009 745.927 -18.11%
2010 501.600 -48.71%
2011 454.997 -10.24%
2012 432.000 -5.32%
2013 10.673.016 95.95%
2014 20.053.000 46.78%
2015 26.022.000 22.94%
2016 28.196.000 7.71%
2017 22.300.000 -26.44%
2018 27.638.000 19.31%
2019 25.345.000 -9.05%
2020 21.255.000 -19.24%
2021 21.943.000 3.14%
2022 26.915.000 18.47%
2023 27.984.000 3.82%
2023 25.353.000 -10.38%
2024 15.612.000 -62.39%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Accelerate Diagnostics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 0
1997 0 0%
1998 956.667 100%
1999 997.830 4.13%
2000 1.527.304 34.67%
2001 709.006 -115.41%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 919.706 100%
2010 869.348 -5.79%
2011 810.078 -7.32%
2012 2.945.309 72.5%
2013 4.312.281 31.7%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Accelerate Diagnostics, Inc. EBITDA
Year EBITDA Growth
1996 1.300.000
1997 700.000 -85.71%
1998 4.239.197 83.49%
1999 175.642 -2313.54%
2000 -1.700.421 110.33%
2001 172.210 1087.41%
2002 -457.312 137.66%
2003 -1.104.863 58.61%
2004 -1.489.626 25.83%
2005 -1.968.098 24.31%
2006 -2.881.204 31.69%
2007 -1.879.437 -53.3%
2008 -1.417.613 -32.58%
2009 -355.625 -298.63%
2010 849.379 141.87%
2011 -168.102 605.28%
2012 -1.177.000 85.72%
2013 -14.925.660 92.11%
2014 -30.562.000 51.16%
2015 -43.683.000 30.04%
2016 -63.656.000 31.38%
2017 -64.107.000 0.7%
2018 -74.991.000 14.51%
2019 -67.434.000 -11.21%
2020 -59.908.000 -12.56%
2021 -68.974.000 13.14%
2022 -59.481.000 -15.96%
2023 -54.464.000 -9.21%
2023 -50.774.000 -7.27%
2024 -30.916.000 -64.23%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Accelerate Diagnostics, Inc. Gross Profit
Year Gross Profit Growth
1996 1.800.000
1997 2.200.000 18.18%
1998 6.227.893 64.68%
1999 1.669.353 -273.07%
2000 923.378 -80.79%
2001 321.020 -187.64%
2002 469.731 31.66%
2003 702.031 33.09%
2004 52.984 -1224.99%
2005 346.602 84.71%
2006 171.097 -102.58%
2007 126.484 -35.27%
2008 465.871 72.85%
2009 1.269.886 63.31%
2010 2.245.628 43.45%
2011 1.121.166 -100.29%
2012 236.000 -375.07%
2013 48.285 -388.76%
2014 122.000 60.42%
2015 147.000 17.01%
2016 246.000 40.24%
2017 3.175.000 92.25%
2018 2.483.000 -27.87%
2019 4.400.000 43.57%
2020 4.459.000 1.32%
2021 -381.000 1270.34%
2022 3.303.000 111.53%
2023 428.000 -671.73%
2023 2.550.000 83.22%
2024 2.704.000 5.7%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Accelerate Diagnostics, Inc. Net Profit
Year Net Profit Growth
1996 1.100.000
1997 1.000.000 -10%
1998 2.878.451 65.26%
1999 70.432 -3986.85%
2000 -922.536 107.63%
2001 -1.546.710 40.35%
2002 -400.733 -285.97%
2003 -1.375.827 70.87%
2004 -909.421 -51.29%
2005 -2.090.800 56.5%
2006 -3.030.621 31.01%
2007 -1.924.243 -57.5%
2008 -1.680.342 -14.51%
2009 -714.197 -135.28%
2010 641.747 211.29%
2011 -378.761 269.43%
2012 -5.311.000 92.87%
2013 -15.281.821 65.25%
2014 -30.933.000 50.6%
2015 -45.498.000 32.01%
2016 -66.374.000 31.45%
2017 -62.882.000 -5.55%
2018 -88.326.000 28.81%
2019 -84.305.000 -4.77%
2020 -78.208.000 -7.8%
2021 -77.702.000 -0.65%
2022 -62.493.000 -24.34%
2023 3.640.000 1816.84%
2023 -61.618.000 105.91%
2024 -46.352.000 -32.93%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Accelerate Diagnostics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 9
1997 2 -700%
1998 4 66.67%
1999 0 0%
2000 -1 100%
2001 -2 50%
2002 0 0%
2003 -1 100%
2004 -1 0%
2005 -2 100%
2006 -3 33.33%
2007 -2 -200%
2008 -2 0%
2009 -1 0%
2010 1 0%
2011 0 0%
2012 -4 100%
2013 -4 0%
2014 -7 42.86%
2015 -10 30%
2016 -13 16.67%
2017 -12 -9.09%
2018 -16 31.25%
2019 -15 -6.67%
2020 -14 -15.38%
2021 -13 -8.33%
2022 -8 -71.43%
2023 0 0%
2023 -5 100%
2024 -2 -100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Accelerate Diagnostics, Inc. Free Cashflow
Year Free Cashflow Growth
1996 1.100.000
1997 800.000 -37.5%
1998 3.469.074 76.94%
1999 995.733 -248.39%
2000 403.610 -146.71%
2001 -132.312 405.04%
2002 -683.425 80.64%
2003 41.994 1727.43%
2004 -1.343.812 103.12%
2005 -1.683.758 20.19%
2006 -2.739.750 38.54%
2007 -1.535.667 -78.41%
2008 -1.081.369 -42.01%
2009 -296.024 -265.3%
2010 -838.803 64.71%
2011 373.145 324.79%
2012 -912.000 140.92%
2013 -10.906.515 91.64%
2014 -20.718.000 47.36%
2015 -38.782.000 46.58%
2016 -55.817.000 30.52%
2017 -58.712.000 4.93%
2018 -68.754.000 14.61%
2019 -65.124.000 -5.57%
2020 -51.756.000 -25.83%
2021 -47.926.000 -7.99%
2022 -49.282.000 2.75%
2023 -41.230.999 -19.53%
2023 -9.011.000 -357.56%
2024 -7.585.000 -18.8%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Accelerate Diagnostics, Inc. Operating Cashflow
Year Operating Cashflow Growth
1996 1.100.000
1997 900.000 -22.22%
1998 3.660.989 75.42%
1999 1.038.289 -252.6%
2000 410.605 -152.87%
2001 -63.735 744.24%
2002 -665.165 90.42%
2003 151.158 540.05%
2004 -1.215.343 112.44%
2005 -1.599.569 24.02%
2006 -2.640.956 39.43%
2007 -1.535.667 -71.97%
2008 -963.728 -59.35%
2009 -225.656 -327.08%
2010 -789.600 71.42%
2011 448.481 276.06%
2012 -816.000 154.96%
2013 -9.748.951 91.63%
2014 -18.785.000 48.1%
2015 -35.126.000 46.52%
2016 -53.408.000 34.23%
2017 -55.746.000 4.19%
2018 -67.756.000 17.73%
2019 -64.794.000 -4.57%
2020 -50.394.000 -28.57%
2021 -47.323.000 -6.49%
2022 -48.728.000 2.88%
2023 -40.196.000 -21.23%
2023 -8.253.000 -387.05%
2024 -7.583.000 -8.84%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Accelerate Diagnostics, Inc. Capital Expenditure
Year Capital Expenditure Growth
1996 0
1997 100.000 100%
1998 191.915 47.89%
1999 42.556 -350.97%
2000 6.995 -508.38%
2001 68.577 89.8%
2002 18.260 -275.56%
2003 109.164 83.27%
2004 128.469 15.03%
2005 84.189 -52.6%
2006 98.794 14.78%
2007 0 0%
2008 117.641 100%
2009 70.368 -67.18%
2010 49.203 -43.02%
2011 75.336 34.69%
2012 96.000 21.53%
2013 1.157.564 91.71%
2014 1.933.000 40.12%
2015 3.656.000 47.13%
2016 2.409.000 -51.76%
2017 2.966.000 18.78%
2018 998.000 -197.19%
2019 330.000 -202.42%
2020 1.362.000 75.77%
2021 603.000 -125.87%
2022 554.000 -8.84%
2023 1.034.999 46.47%
2023 758.000 -36.54%
2024 2.000 -37800%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Accelerate Diagnostics, Inc. Equity
Year Equity Growth
1996 1.900.000
1997 9.200.000 79.35%
1998 12.355.892 25.54%
1999 12.235.964 -0.98%
2000 11.262.187 -8.65%
2001 9.611.396 -17.18%
2002 13.744.648 30.07%
2003 12.729.144 -7.98%
2004 11.736.640 -8.46%
2005 9.668.340 -21.39%
2006 6.739.320 -43.46%
2007 4.880.207 -38.09%
2008 4.412.971 -10.59%
2009 3.894.494 -13.31%
2010 4.909.778 20.68%
2011 4.815.476 -1.96%
2012 14.835.567 67.54%
2013 41.516.780 64.27%
2014 65.991.000 37.09%
2015 133.018.000 50.39%
2016 77.816.000 -70.94%
2017 119.920.000 35.11%
2018 57.375.000 -109.01%
2019 -7.379.000 877.54%
2020 -62.812.000 88.25%
2021 -35.071.000 -79.1%
2022 -22.264.000 -57.52%
2023 -19.888.000 -11.95%
2023 -35.033.000 43.23%
2024 -34.887.000 -0.42%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Accelerate Diagnostics, Inc. Assets
Year Assets Growth
1996 2.300.000
1997 9.800.000 76.53%
1998 13.974.777 29.87%
1999 14.072.543 0.69%
2000 13.105.718 -7.38%
2001 10.731.744 -22.12%
2002 15.023.934 28.57%
2003 13.745.373 -9.3%
2004 12.724.732 -8.02%
2005 11.008.067 -15.59%
2006 7.848.223 -40.26%
2007 6.138.087 -27.86%
2008 5.827.466 -5.33%
2009 5.231.435 -11.39%
2010 6.268.966 16.55%
2011 6.264.338 -0.07%
2012 17.213.742 63.61%
2013 43.430.377 60.36%
2014 69.801.000 37.78%
2015 139.324.000 49.9%
2016 82.852.000 -68.16%
2017 126.727.000 34.62%
2018 185.265.000 31.6%
2019 134.424.000 -37.82%
2020 93.425.000 -43.88%
2021 83.047.000 -12.5%
2022 65.015.000 -27.74%
2023 31.366.000 -107.28%
2023 39.324.000 20.24%
2024 22.867.000 -71.97%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Accelerate Diagnostics, Inc. Liabilities
Year Liabilities Growth
1996 400.000
1997 600.000 33.33%
1998 1.618.885 62.94%
1999 1.836.579 11.85%
2000 1.843.531 0.38%
2001 1.120.348 -64.55%
2002 1.279.286 12.42%
2003 1.016.229 -25.89%
2004 988.092 -2.85%
2005 1.339.727 26.25%
2006 1.108.903 -20.82%
2007 1.257.880 11.84%
2008 1.414.495 11.07%
2009 1.336.941 -5.8%
2010 1.359.188 1.64%
2011 1.448.862 6.19%
2012 2.378.175 39.08%
2013 1.913.597 -24.28%
2014 3.810.000 49.77%
2015 6.306.000 39.58%
2016 5.036.000 -25.22%
2017 6.807.000 26.02%
2018 127.890.000 94.68%
2019 141.803.000 9.81%
2020 156.237.000 9.24%
2021 118.118.000 -32.27%
2022 87.279.000 -35.33%
2023 51.254.000 -70.29%
2023 74.357.000 31.07%
2024 57.754.000 -28.75%

Accelerate Diagnostics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.53
Net Income per Share
-1.64
Price to Earning Ratio
-1.17x
Price To Sales Ratio
3.72x
POCF Ratio
-1.38
PFCF Ratio
-1.36
Price to Book Ratio
-1.27
EV to Sales
6.5
EV Over EBITDA
-2.07
EV to Operating CashFlow
-2.47
EV to FreeCashFlow
-2.37
Earnings Yield
-0.86
FreeCashFlow Yield
-0.74
Market Cap
0,05 Bil.
Enterprise Value
0,08 Bil.
Graham Number
7.48
Graham NetNet
-1.94

Income Statement Metrics

Net Income per Share
-1.64
Income Quality
0.85
ROE
1.31
Return On Assets
-1.66
Return On Capital Employed
-4.42
Net Income per EBT
1.02
EBT Per Ebit
0.89
Ebit per Revenue
-3.43
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
1.78
Stock Based Compensation to Revenue
0.45
Gross Profit Margin
0.17
Operating Profit Margin
-3.43
Pretax Profit Margin
-3.05
Net Profit Margin
-3.11

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.39
Free CashFlow per Share
-1.45
Capex to Operating CashFlow
-0.04
Capex to Revenue
0.11
Capex to Depreciation
0.41
Return on Invested Capital
-5.89
Return on Tangible Assets
-1.66
Days Sales Outstanding
68.45
Days Payables Outstanding
135.93
Days of Inventory on Hand
116.54
Receivables Turnover
5.33
Payables Turnover
2.69
Inventory Turnover
3.13
Capex per Share
0.06

Balance Sheet

Cash per Share
0,42
Book Value per Share
-1,51
Tangible Book Value per Share
-1.51
Shareholders Equity per Share
-1.51
Interest Debt per Share
2.24
Debt to Equity
-1.21
Debt to Assets
1.85
Net Debt to EBITDA
-0.88
Current Ratio
1.28
Tangible Asset Value
-0,03 Bil.
Net Current Asset Value
-0,04 Bil.
Invested Capital
8572000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
3236000
Debt to Market Cap
0.93

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Accelerate Diagnostics, Inc. Dividends
Year Dividends Growth

Accelerate Diagnostics, Inc. Profile

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

CEO
Mr. Jack Phillips
Employee
134
Address
3950 South Country Club Road
Tucson, 85714

Accelerate Diagnostics, Inc. Executives & BODs

Accelerate Diagnostics, Inc. Executives & BODs
# Name Age
1 Mr. John Meduri
Chief Strategy Officer
70
2 Laura Pierson
Investor Relations Officer
70
3 Mr. David Patience
Chief Financial Officer
70
4 Mr. Lawrence Michael Mertz
Chief Technology Officer
70
5 Ms. Maya Gowri
Senior Vice President & Head of Operations
70
6 Mr. Chris Thode
Senior Vice President of US Commercial
70
7 Mr. Jack Phillips
Chief Executive Officer, President & Director
70
8 Ms. Rita Boukamel
Senior Vice President & Head of EMEA
70

Accelerate Diagnostics, Inc. Competitors